Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:38:19.977Z.
Calculation as of: 2026-10-06T19:38:19.977Z.
Quote observation: 2026-10-06T19:35:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d4773eeabafa62aebeff6315a1128d32b86b9098e0544dfe9acdb21c4fcfe70f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$151.58M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.89M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$159.22M
EV/EBITDA Ratio
N/A
TTM Avg
159.13x
3Y Avg
159.13x
5Y Avg
159.13x
Market Cap
$147.35M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $153.09M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.90M | N/A | 29.09x | 58.55x | 59.27x |
| Veraxa Biotech Holding AG (VRXA)vs › | $149.89M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A | 159.13x | 159.13x | 159.13x |
| PepGen Inc. (PEPG)vs › | $159.44M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $147.35M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $146.83M | N/A | 183.85x | 184.46x | 184.46x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
